Yukon Wealth Management Inc. Invests $1.04 Million in Johnson & Johnson $JNJ

Key Points

• Yukon Wealth Management purchased 4,101 Johnson & Johnson shares worth approximately $1.04 million in the second quarter. Institutional investors collectively own 69.55% of JNJ.
• Johnson & Johnson exceeded quarterly expectations, reporting $2.90 in EPS and $25.31 billion in revenue, with revenue up 6.6% year over year. Analysts maintain a consensus “Moderate Buy” rating and an average price target of $272.83.
• The company declared a quarterly dividend of $1.34 per share, or $5.36 annualized, yielding approximately 1.9%. Insiders sold 97,569 shares worth $25.5 million during the last quarter.

Yukon Wealth Management Inc. bought a new stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 4,101 shares of the company's stock, valued at approximately $1,042,000.

A number of other hedge funds have also recently added to or reduced their stakes in JNJ. Blueline Advisors LLC purchased a new position in Johnson & Johnson in the fourth quarter valued at $25,000. Matrix Trust Co boosted its stake in shares of Johnson & Johnson by 56.2% during the 2nd quarter. Matrix Trust Co now owns 150 shares of the company's stock worth $38,000 after acquiring an additional 54 shares in the last quarter. E Fund Management Hong Kong Co. Ltd. grew its position in shares of Johnson & Johnson by 946.7% during the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 157 shares of the company's stock valued at $32,000 after acquiring an additional 142 shares during the period. MidAtlantic Capital Management Inc. acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at about $37,000. Finally, Semmax Financial Advisors Inc. increased its stake in shares of Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company's stock valued at $31,000 after purchasing an additional 72 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $275.12 on Tuesday. The business has a 50 day simple moving average of $262.32 and a two-hundred day simple moving average of $245.30. Johnson & Johnson has a 12 month low of $173.33 and a 12 month high of $281.07. The stock has a market capitalization of $663.01 billion, a P/E ratio of 31.88, a PEG ratio of 2.63 and a beta of 0.24. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The firm had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. During the same period in the previous year, the company posted $2.77 earnings per share. The business's revenue was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, analysts predict that Johnson & Johnson will post 11.61 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be given a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date is Tuesday, August 25th. Johnson & Johnson's dividend payout ratio is 62.11%.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Argus set a $300.00 price target on Johnson & Johnson in a research report on Wednesday, July 29th. Stifel Nicolaus set a $260.00 price objective on Johnson & Johnson in a research report on Wednesday, July 15th. Morgan Stanley increased their target price on Johnson & Johnson from $284.00 to $294.00 and gave the company an "overweight" rating in a research report on Thursday, July 16th. HSBC set a $290.00 price target on shares of Johnson & Johnson and gave the company a "buy" rating in a research note on Monday, July 6th. Finally, Wall Street Zen cut shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a research report on Saturday, August 1st. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $272.83.

Insider Transactions at Johnson & Johnson

In related news, EVP Elizabeth Forminard sold 15,918 shares of the business's stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the transaction, the executive vice president directly owned 16,994 shares in the company, valued at approximately $4,367,458. The trade was a 48.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Vanessa Broadhurst sold 23,054 shares of the company's stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the sale, the executive vice president directly owned 23,003 shares of the company's stock, valued at approximately $5,779,963.81. This represents a 50.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 97,569 shares of company stock valued at $25,476,044. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.